Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8126995 | 0.96 | ADORA2A (0.46) | TK1ADORA2ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3817534 | 0.89 | ACHE (0.34) | ADORA2ANPC1ALDH1A1MAPTTHRB | |
| SCHEMBL8114300 | 0.87 | CSNK2A2 (0.43) | ADORA2ACSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL8121668 | 0.86 | ADORA2A (0.46) | ADORA2AADORA1NPC1ALDH1A1MAPT | |
| SCHEMBL7551424 | 0.86 | CHRNE (0.33) | ADORA2ACSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL3178293 | 0.85 | ALDH1A1 (0.33) | ADORA2ANPC1ALDH1A1MAPTTHRB | |
| SCHEMBL4917188 | 0.82 | NPC1 (0.32) | NPC1ALDH1A1MAPTTHRBRAB9A | |
| SCHEMBL3162983 | 0.81 | ALDH1A1 (0.34) | NPC1ALDH1A1MAPTTHRBRAB9A | |
| SCHEMBL14516490 | 0.80 | TLR7 (0.41) | NPC1ALDH1A1MAPTTHRBRAB9A | |
| Dimethylformamide SCHEMBL9048332 | 0.78 | CSNK2A2 (0.36) | ADORA2ACSNK2A2CSNK2BCSNK2A1CSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-7648997-B2 | Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1653955-A4 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1653914-A4 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-1653914-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1653955-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005018551-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018556-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | IFNG, IRF3, IL2 | TK1 241/4885ADORA2A 1737/4885CSNK2A2 1357/4885 |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | TK1 224/4885ADORA2A 2889/4885CSNK2A2 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.